ArticleCell communication and signaling : CCS2025
Enhancing intestinal epithelial microtubule stability could alleviate IBD symptoms.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progress in targeting the NLRP3 signaling pathway for inflammatory bowel disease (Review).Molecular medicine reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is characterized by epithelial barrier dysfunction, where in the cytoskeleton, especially actin microfilaments and intermediate filaments, has been extensively investigated for its critical role in maintaining the structural integrity of the epithelial barrier. However, the specific contribution of microtubules to this process remains unknown.
methodsIn this study, we analyzed the expression of acetylated α-tubulin (Ac-α-tubulin), a marker of stable microtubule structures, in colonic tissues from IBD patients and healthy controls using immunofluorescence. We also employed dextran sulfate sodium (DSS) to induce colitis in murine models and stimulated Caco-2 cells with tumor necrosis factor-alpha (Tnfα) to elucidate the subsequent alterations in microtubule dynamics. We subsequently evaluated the impact of microtubule-associated protein kinase 2 (MARK2) deficiency on microtubule dynamics, epithelial permeability, and inflammation. This was accomplished using both stable MARK2 knockdown Caco-2 cell lines and intestinal epithelial-specific MARK2 conditional knockout (MARK2
resultsOur findings revealed a significant reduction in Ac-α-tubulin expression in both IBD patient tissues and the DSS-induced colitis model. Treatment with PTX significantly enhanced Ac-α-tubulin levels and mitigated colitis symptoms in DSS-induced mice. Furthermore, MARK2 knockdown decreased Ac-α-tubulin expression and increased paracellular permeability, which could be reversed by AGK2 or PTX treatment.
conclusionThis study provides new insights into the pathogenesis of IBD by elucidating the role of microtubules in epithelial barrier disruption. Our findings propose microtubule-modulating therapeutics as a potential novel treatment strategy for IBD, highlighting the importance of stabilizing microtubules to restore epithelial integrity and reduce inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.